| Dividend per share, FY2025 | ₩650 | Yield at last close | 2.36% |
| Yield reported by the company (FY-end) | 2.10% | Payout ratio (consolidated) | 25.5% |
| Total cash dividends | ₩15.7bn | Earnings per share | ₩2,534 |
| Consecutive years paid (on file) | 12 | DPS growth, 5-year CAGR | +14.9% |
| Dividend decisions filed in 2026 | 0 | Preferred share DPS | ₩675 |
| Fiscal year | DPS (common) | Change | Yield (FY-end) | Payout | Total cash ₩bn | EPS | DPS (preferred) |
|---|---|---|---|---|---|---|---|
| FY2025 | ₩650 | +44.4% | 2.10% | 25.5% | 15.7 | ₩2,534 | ₩675 |
| FY2024 | ₩450 | +12.5% | 1.90% | 17.0% | 11.1 | ₩2,642 | ₩475 |
| FY2023 | ₩400 | +6.7% | 1.10% | 25.1% | 9.7 | ₩1,611 | ₩425 |
| FY2022 | ₩375 | +15.4% | 1.90% | 27.6% | 8.8 | ₩1,331 | ₩400 |
| FY2021 | ₩325 | 0.0% | 1.40% | — | 7.4 | ₩-42 | ₩350 |
| FY2020 | ₩325 | 0.0% | 0.90% | — | 7.1 | ₩-656 | ₩350 |
| FY2019 | ₩325 | 0.0% | 1.10% | — | 7.0 | ₩-1,129 | ₩350 |
| FY2018 | ₩325 | +18.2% | 0.80% | — | 7.0 | ₩343 | ₩350 |
| FY2017 | ₩275 | +10.0% | 0.60% | — | 5.8 | ₩-75 | ₩300 |
| FY2016 | ₩250 | +66.7% | 0.50% | — | 5.2 | ₩-616 | ₩275 |
| FY2015 | ₩150 | +20.0% | 0.40% | 138.4% | 2.7 | ₩69 | ₩175 |
| FY2014 | ₩125 | — | 0.80% | — | 2.7 | ₩-206 | ₩150 |
No filings on file yet.
| Symbol | Last Price |
|---|---|
| 476830Rznomics, Inc. | ₩28,200 +6.8% |
| 003850Boryung Corporation | ₩9,040 +1.6% |
| 950260Ingenia Therapeutics Inc.(reg.s) | ₩15,580 -1.5% |
| 085660Chabiotech Co., Ltd. | ₩8,090 +2.1% |
| 476060Onconic Therapeutics, Inc. | ₩16,440 -3.9% |
| 041960Komipharm International Co., Ltd. | ₩9,710 +3.5% |
| 317450Myungin Pharm | ₩44,650 +0.0% |
| 456160G2GBIO, Inc. | ₩37,950 +5.7% |
| 019170Shinpoong Pharmaceutical Co., Ltd. | ₩10,010 -0.9% |
| 358570GI Innovation, Inc. | ₩8,090 +6.2% |